Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-20. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
=== Defendants === Aside from Agüero, who is being tried as the sole person responsible for the murders, provincial and hospital officials are on trial for their alleged failure to inform authorities of the deaths of healthy babies. Among the officials are the former Health Minister of Córdoba, Diego Cardozo, the former head of the hospital, Liliana Asís, as well as several hospital personnel, including the head of the nursing department, Blanca Alicia Ariza, the head of the neonatal unit, Marta Gómez, and other doctors and politicians.
Sjögren's disease (SjD), previously known as Sjögren syndrome or Sjögren's syndrome (SjS, SS), is a long-term autoimmune disease that primarily affects the body's exocrine glands, particularly the lacrimal and salivary glands. Common symptoms include dry mouth and dry eyes, and in a subset of patients can seriously affect other organ systems, such as the lungs, kidneys, and nervous system.
Prostatitis is inflammation of the prostate gland. It can be caused by infection with bacteria, or other noninfective causes. Inflammation of the prostate can cause painful urination or ejaculation, groin pain, difficulty passing urine, or constitutional symptoms such as fever or tiredness. When inflamed, the prostate becomes enlarged and is tender when touched during digital rectal examination. The bacteria responsible for the infection may be detected by a urine culture. Acute prostatitis and chronic bacterial prostatitis are treated with antibiotics. Chronic non-bacterial prostatitis, or male chronic pelvic pain syndrome is treated by a large variety of modalities including the medications alpha blockers, non-steroidal anti-inflammatories and amitriptyline, antihistamines, and other anxiolytics. Other treatments that are not medications may include physical therapy, psychotherapy, nerve modulators, and surgery. More recently, a combination of trigger point and psychological therapy has proved effective for category III prostatitis as well.
Sources: en.wikipedia.org
Sequest (often stylized as SEQUEST) is a tandem mass spectrometry data analysis program used for protein identification. Sequest identifies collections of tandem mass spectra to peptide sequences that have been generated from databases of protein sequences.
{\displaystyle {\begin{aligned}{\frac {dS}{dt}}&=\mu N-\mu S-{\frac {\beta IS}{N}}\\[8pt]{\frac {dE}{dt}}&={\frac {\beta IS}{N}}-(\mu +a)E\\[8pt]{\frac {dI}{dt}}&=aE-(\gamma +\mu )I\\[8pt]{\frac {dR}{dt}}&=\gamma I-\mu R.\end{aligned}}}
Nurses affiliated with the New Zealand Nurses Organisation in Auckland and Whangārei commence industrial action to protest staff shortages. A member of the New Zealand Defence Force pleads guilty before a court-martial to attempted espionage on behalf of a foreign country, in the first espionage conviction in New Zealand. He is sentenced to two years' imprisonment on 20 August. 19 August: The Interislander and Bluebridge cancel several ferry sailings due to strong swells in the Cook Strait. Foreign Minister Winston Peters recalls Trevor Mallard as New Zealand ambassador to Ireland, designating Angela Hassan-Sharp as his successor. Employees of media company Stuff vote to take strike action to protest their employer's plan to split their collective bargaining agreement. 20 August: Secondary school teachers affiliated with the Post Primary Teachers' Association went on strike for a day after rejecting the Government's one percent pay rise offer. The New Zealand Cabinet agrees to draft legislation banning greyhound racing in New Zealand. 21 August: Defence Minister Judith Collins and Foreign Minister Winston Peters announce that the Government will purchase two new Airbus A321XLR jets and five MH-60R Seahawks for the New Zealand Defence Force. Carter Holt Harvey proposes closing its Eves Valley Sawmill in the Tasman District, potentially affecting 142 jobs. Airliner Jetstar admits to 20 charges of breaching the Fair Trading Act 1986 by misleading customers about compensation.
Chemoreceptor A sensory receptor that responds to chemical stimuli, such as taste molecules or blood oxygen levels. Located in tissues including the tongue, nasal cavity, and blood vessels. Cholinergic Refers to cells or systems that use acetylcholine as a neurotransmitter. Cholinergic neurons are involved in memory, attention, and muscle activation. Choroid plexus A network of cells located in the ventricles of the brain that produces cerebrospinal fluid and contributes to the maintenance of the blood–CSF barrier. Chromatolysis A cellular response to neuronal injury, characterized by swelling of the cell body and dispersal of Nissl substance, indicating a disruption in protein synthesis. Cingulate cortex A part of the limbic system located on the medial side of the cerebral hemispheres. It is involved in emotion formation, pain perception, decision-making, and cognitive control. Cognition The set of mental processes involved in acquiring knowledge and understanding through thought, experience, and the senses. Includes attention, memory, language, and problem-solving. Cognitive neuroscience A field that studies the biological processes underlying cognition, focusing on how brain structure and function give rise to mental activities. Commissure A bundle of nerve fibers that connects corresponding areas between the two hemispheres of the brain. The largest is the corpus callosum. Conditioned stimulus In classical conditioning, a previously neutral stimulus that, after being paired with an unconditioned stimulus, elicits a learned response.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.